On April 13, 2023 Kelun-Biotech, a subsidiary of China’s Kelun Pharmaceutical is collaborating with Panolos Bioscience, a South Korean biotech company, join forces to develop a dual-targeted immune-oncology drug named PKB01 (Press release, Kelun, APR 18, 2023, View Source [SID1234633690]). The partnership aims to combine Kelun-Biotech’s immunotherapy candidate with Panolos’ multiple specific drug generation platform. The focus will be on optimizing the candidate material for preclinical studies, with clinical trials planned for the following years.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Panolos will acquire global development and commercialization rights for the candidate material, excluding China, and will secure a portfolio of immune-oncology pipelines with First-In-Class potential. Kelun-Biotech’s immunotherapy candidate material is an immune checkpoint inhibitor that targets immune checkpoint molecules expressed in immune and cancer cells. The specific target information for this candidate material has not yet been released.
The dual-targeted therapy PKB01 aims to suppress tumor growth by targeting VEGF family members and enhance immune activation by inhibiting immune checkpoint molecules. This therapy may also overcome drug resistance, a limitation of current monotherapy treatments. Panolos and Kelun-Biotech hope to develop next-generation dual-targeted anti-cancer drugs that combine the advantages of both companies’ technologies to help cancer patients.
In Apr 06, Kick off ceremony, Panolos CEO, Dr. Hyeseong Lim said "Our collaboration aims to revolutionize immuno-oncology and give new hope to cancer patients around the world. Created by the combination of Panolos’ αART platform and Kelun-Biotech’s proprietary information of anti-PD-1, PKB01 will have an unique opportunity to create a strong dual-target therapy that will overcome current treatment limitations. This close partnership will benefit both companies, and ultimately benefit all the patients we serve".